Are the Rates of Stroke Similar in TAVR and Surgery?

Courtesy of Dr. Carlos Fava.

Stroke is one of the most undesirable complications we can face and, regarding transcatheter aortic valve replacement (TAVR), major studies presented have rates of stroke of about 4%. In others, rates have been slightly higher.

This meta-analysis included 5 randomized studies between 2011 and 2017: PARTNER, CoreVALVE, NOTION, PARTNER 2, and SURTAVI. Among included patients, 2755 underwent TAVR and 2659 underwent surgical aortic valve replacement. The rates of stroke were analyzed in both groups.

 

At 30 days, no differences were observed in the risk for stroke (relative risk [RR]: 0.85; 95% confidence interval [CI]: 0.59-1.22), major stroke (RR: 0.89; 95% CI: 0.53-1.51), or any kind of cerebrovascular event (RR: 0.94; 95% CI: 0.75-1.17) between strategies.


Read also: Angina Is as Subjective as Any Other Pain.


After a 1-year follow-up, no differences were observed either regarding the risk for stroke (RR: 0.92; 95% CI: 0.69-1.22), major stroke (RR: 0.92; 95% CI: 0.62-1.37), and any kind of cerebrovascular event (RR: 1.03; 95% CI: 0.79-1.33).

 

There was also an analysis between 30 days and 1 year, which showed no differences between TAVR and surgery.

 

Conclusion

This meta-analysis comparing TAVR and surgical aortic valve replacement showed comparable risk for stroke or any cerebrovascular event.

 

Editorial Comment

This meta-analysis shows similar risk for both strategies, but we must take into account that the studies analyzed are the first that began to show the benefit of TAVR with first-generation valves.

 

Second-generation valves and greater operator experience have proved to result in a lower risk of cerebrovascular events. Furthermore, there are increasingly more studies including cerebral protection systems in which the number of events is surely decreasing, thus ensuring higher TAVR effectiveness.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Comparative Analysis of Cerebrovascular Events in Transcatheter and Surgical Aortic Valve Replacement: A Systematic Review and Meta-Analysis of Randomised Trials.

Reference: Divyanshu Mohananey, EuroIntervention 2018;14:69-77.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...